NASDAQ:TBPH Theravance Biopharma (TBPH) Stock Price, News & Analysis $8.58 +0.14 (+1.66%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Theravance Biopharma Stock (NASDAQ:TBPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Theravance Biopharma alerts:Sign Up Key Stats Today's Range$8.41▼$8.5950-Day Range$8.44▼$10.0852-Week Range$7.44▼$10.44Volume166,562 shsAverage Volume144,656 shsMarket Capitalization$421.91 millionP/E RatioN/ADividend YieldN/APrice Target$13.75Consensus RatingHold Company OverviewTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Read More… Theravance Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks50th Percentile Overall ScoreTBPH MarketRank™: Theravance Biopharma scored higher than 50% of companies evaluated by MarketBeat, and ranked 600th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingTheravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageTheravance Biopharma has received no research coverage in the past 90 days.Read more about Theravance Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Theravance Biopharma are expected to grow in the coming year, from ($1.09) to $0.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theravance Biopharma is -8.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theravance Biopharma is -8.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheravance Biopharma has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Theravance Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.62% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 21.2, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently decreased by 3.93%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTheravance Biopharma does not currently pay a dividend.Dividend GrowthTheravance Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.62% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 21.2, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently decreased by 3.93%, indicating that investor sentiment is improving. News and Social Media3.4 / 5News Sentiment1.08 News SentimentTheravance Biopharma has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Theravance Biopharma this week, compared to 2 articles on an average week.Search Interest1 people have searched for TBPH on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,000.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Theravance Biopharma is held by insiders.Percentage Held by Institutions99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Theravance Biopharma's insider trading history. Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Stock News HeadlinesQ2 EPS Estimate for Theravance Biopharma Boosted by AnalystJanuary 18 at 2:55 AM | americanbankingnews.comAnalysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH)January 7, 2025 | uk.finance.yahoo.comWall St turns to THIS catalyst after Trump’s inaugurationWall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger than his inauguration. As soon as January 29th…January 20, 2025 | Timothy Sykes (Ad)Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare ConferenceDecember 17, 2024 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceNovember 20, 2024 | prnewswire.comTheravance Biopharma’s Third Quarter 2024 Financial InsightsNovember 14, 2024 | markets.businessinsider.comTheravance Biopharma (TBPH) Receives a Hold from Evercore ISINovember 14, 2024 | markets.businessinsider.comTheravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...November 13, 2024 | uk.finance.yahoo.comSee More Headlines TBPH Stock Analysis - Frequently Asked Questions How have TBPH shares performed this year? Theravance Biopharma's stock was trading at $9.41 at the beginning of the year. Since then, TBPH stock has decreased by 8.8% and is now trading at $8.58. View the best growth stocks for 2025 here. How were Theravance Biopharma's earnings last quarter? Theravance Biopharma, Inc. (NASDAQ:TBPH) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.16. The biopharmaceutical company earned $16.87 million during the quarter, compared to analysts' expectations of $16.11 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 24.79% and a negative net margin of 78.18%. Who are Theravance Biopharma's major shareholders? Theravance Biopharma's top institutional investors include SG Americas Securities LLC (0.04%). Insiders that own company stock include Richard A Graham and Rhonda Farnum. View institutional ownership trends. How do I buy shares of Theravance Biopharma? Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings11/12/2024Today1/20/2025Next Earnings (Estimated)2/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CUSIPN/A CIK1583107 Webwww.theravance.com Phone(650) 808-6000FaxN/AEmployees359Year FoundedN/APrice Target and Rating Average Stock Price Target$13.75 High Stock Price Target$21.00 Low Stock Price Target$9.00 Potential Upside/Downside+60.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,190,000.00 Net Margins-78.18% Pretax Margin-64.39% Return on Equity-24.79% Return on Assets-13.43% Debt Debt-to-Equity RatioN/A Current Ratio4.97 Quick Ratio4.97 Sales & Book Value Annual Sales$63.19 million Price / Sales6.68 Cash FlowN/A Price / Cash FlowN/A Book Value$4.28 per share Price / Book2.00Miscellaneous Outstanding Shares49,174,000Free Float45,781,000Market Cap$421.91 million OptionableOptionable Beta0.21 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:TBPH) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.